In summary, while we cannot conclusively rule out that alteration of the TAD boundary is responsible for this phenotype, our results strongly suggested that removal of these CTCF sites in humans alters the interaction between ZRS and the SHH promoter, likely leading to the acheiropodia phenotype. The gene discussed is SHH; the disease is Acheiropodia.